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Pharmacotherapeutic 
approaches in the 
treatment of 
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia 
and accounts for major cognitive impairment in the elderly. It is 
a progressive neurodegenerative disorder with distinct pathology. 
At present, the pharmacotherapy of AD involves the use of 
acetylcholinesterase inhibitors and the N-methyl-D-aspartate 
(NMDA) receptor antagonist memantine. The former imply 
neuroprotection hence slowing disease progression while the 
latter may block neuronal excitotoxicity. 
Charles Scerri BPharm (Hons) MPhil PhD (Dundee) CBiol MIBiol EurProBiol
Introduction
AD is the most common form of 
dementia accounting for about 50-60% 
of the cases. Its prevalence increases 
exponentially, from about 2-% of the 
population at age 65 to nearly 7% after 
the age of 85. Given the trend towards 
an increase in the elderly population, the 
prevalence of AD is expected to double in 
the next forty to fifty years. Although no 
epidemiological studies have been carried 
out locally, it is estimated that the number 
of current cases in Malta almost reaches 
the ,000 figure. In addition to the huge 
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costs of treating AD, its psychological and 
social burden on caregivers and society 
are enormous. Caregivers usually become 
depressed, increasing their own use of 
medical resources, and are forced to reduce 
or terminate employment. Therefore, any 
interventions that slow down the rate of 
disease progression even modestly will have 
a major impact on public health.1
AD is an insidious neurodegenerative 
malady characterised by the presence of 
amyloid plaque deposits and neurofibrillary 
tangles in the brain in association 
with significant loss of cholinergic cell 
population in areas of the brain associated 
with learning and memory formation.2 
These pathological lesions and imbalance 
in cholinergic neurotransmission accelerate 
neuronal death.
The first stages of the disease is 
principally characterised by a decline in 
memory, especially loss of recent memory. 
Increasing signs of faulty judgment and 
personality changes also occur during this 
stage. At a later stage, memory decline 
worsens whereas language, attention, 
and executive functions become gradually 
impaired with patients losing the ability 
to perform activities of daily living such 
as dressing, washing and eating. Finally, 
the disease becomes so debilitating that 
the patients become mute, incontinent and 
unable to walk, with the consequence of 
becoming bedridden and prone to illness 
and infection.
Acetylcholinesterase Inhibitors
Acetylcholinesterase inhibitors (AChEIs) 
were the first pharmacological treatments 
for AD approved by the US Food and Drug 
Administration (FDA). Currently four AChEIs 
are clinically available: tacrine (Cognex®), 
donepezil (Aricept®), rivastigmine (Exelon®) 
and galantamine (Reminyl®). Their major 
therapeutic effect is reported to be their 
ability to maintain cognitive function 
compared with placebo over a three year 
treatment period or even less.,5 Some 
studies also suggest that these drugs can 
stabilise and even reverse the neurotoxic 
effects of AD thus delaying the disease 
progression, especially if administered early 
in the course of the disease benefiting 
patients with mild to moderate AD. 
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Rivastigmine is also capable of blocking 
the action of another cholinesterase 
enzyme, butyrylcholinesterase (BuChE), 
which increases considerably in the brain 
of patients with AD changing from a ratio 
of 99:1 to 2:1.6 This may have a favourable 
effect on sustained cholinesterase inhibition 
and subsequent disease stabilisation. On 
the other hand, galantamine’s mechanism 
of action is sufficiently different from 
that of other AChEIs as it also acts on the 
nicotinic acetylcholine receptor (nAChR) 
sites increasing the receptor responsiveness 
to acetylcholine (ACh) facilitating its ionic 
channel opening.7 Tacrine is rarely used 
nowadays because of its frequent dosing 
and the need to monitor liver enzymes for 
the development of hepatotoxicity.2
Nausea, vomiting, diarrhoea, dizziness, 
and anorexia are the most common adverse 
effects associated with acetylcholinesterase 
therapy (Table 1) and occur more frequently 
during dose escalation than during 
maintenance.8 Gastrointestinal effects can 
be minimised by concurrent administration 
of food and the use of an anti-emetic. 
Insomnia, fatigue and muscle cramps 
occur less frequently whereas particular 
attention must be given in patients with 
bradycardia.9 These drugs become inefficient 
in the treatment of severe forms of AD 
during which cholinergic cell population 
is significantly low in various areas of the 
brain.
The mode of action by which these 
drugs act is by blocking the breakdown of 
the neurotransmitter ACh. By inhibiting the 
enzyme acetylcholinesterase, the levels of 
the neurotransmitter at cholinergic synapses 
increase. 
Acetylcholinesterase has also been 
found to promote the formation of amyloid 
plaques, thus inhibiting this enzyme by 
properly designed AChEIs might not only 
provide symptomatic relief but also inhibit 
the progression of the disease itself.8
• Alzheimer’s disease should not be confounded with the mild cognitive decline that 
occurs in normal ageing. AD is a disease involving extensive impairment in various 
domains of cognition that are not characteristic of the normal ageing process.
• AD is usually accompanied by disturbance in behaviour manifesting itself in anxiety, 
depression, agitation, hallucinations, delusions, inappropriate behaviour and eating 
disorders. These neuropsychiatric disorders, which may occur in a considerable 
number of cases, are one of the main causes of care-giver stress.
• Health care professionals should be aware of the symptoms that characterise the 
disease, and if AD (or any other form of dementia) is suspected, the cases should 
be referred for consultation. Different forms of testing may be adopted including 
neuroimaging techniques as well as using assessment scales such as the Mini-Mental 
State Examination (MMSE).
• Community studies show that care-givers of AD patients are under significant amount 
of psychological stress with the majority of them ending up needing psychiatric care. 
Carers should be helped and provided with the necessary information of the best 
practices available in care-giving. In the local scene, organisations such as the Malta 
Dementia Society (www.maltadementiasociety.org.mt), aim to provide the best 
information about dementia care not only to carers and health professionals but 
also to the public in general.
Practice Points
Table 1
Characteristics of pharmacological agents commonly used in the management of AD
Medication Pharmacological class Mode of action Recommended use Potential adverse effects
Donepezil hydrochloride AChEI Block acetylcholinesterase  Mild-to-moderate AD Anorexia, diarrhoea, dreams, 
(Aricept®)  enzyme  fatigue, insomnia, muscle
    cramps, nausea, vomiting,
    weight loss
    
Rivastigmine tartrate AChEI Block both acetyl- and  Mild-to-moderate AD Anorexia, diarrhoea, nausea, 
(Exelon®)  butyryl-cholinesterase  vomiting, weight loss
  enzymes 
    
Galantamine  AChEI Block acetylcholinesterase  Mild-to-moderate AD Anorexia, nausea, vomiting, 
hydrobromide  enzyme. Allosterically  weight loss
(Reminyl®)  stimulates nAChRs
    
Memantine  Glutamatergic-system  Partial NMDA-receptor Moderate-to-severe AD Agitation, constipation,
hydrochloride  modifier antagonist  dizziness, hallucinations, 
(Axura®, Ebixa®)    headache, insomnia
 
AChEI: acetylcholinesterase inhibitor; AD: Alzheimer’s disease; nAChRs: nicotinic acetylcholine receptors; NMDA: N-methyl-D-aspartate
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Glutamatergic-transmission 
modifiers
Recent research indicates that the 
excitatory neurotransmitter glutamate 
may play an important role in the 
neurochemistry of AD. Glutamatergic 
neurotransmission has been shown to be 
important in learning and memory and is 
severely disrupted in AD. Overstimulation 
of the NMDA receptor by glutamate leads to 
an overload of intracellular calcium bringing 
about neuronal death which is characteristic 
of AD and other neurodegenerative 
disorders.10 Memantine (Axura®, Ebixa®), a 
non-competitive antagonist with moderate 
affinity for the NMDA receptor, appears to 
block pathologic neural toxicity associated 
with prolonged glutamate release.11 
Therapeutic doses are well tolerated and do 
not appear to interfere with the acquisition 
or processing of cognitive information 
in which the NMDA receptor plays an 
important role.12 Memantine has been shown 
to improve the symptoms and reduce the 
rate of clinical deterioration among patients 
with moderate to severe AD and was 
approved by the FDA for this indication in 
October 200.  In randomised clinical trials, 
the drug demonstrated the ability to delay 
cognitive and functional decline without 
a significance incidence of serious adverse 
events.1,1 Some studies also suggest that 
the efficacy of memantine in combination 
with AChEIs therapy may be greater than 
AChEIs alone significantly improving 
activities of daily living. This combination 
was also found to be well tolerated by the 
majority of AD patients with no serious 
adverse drug reactions reported.15
Discussion
As recently as fifteen years ago, there 
was no effective therapeutic agent for 
symptomatic relief of AD, let alone one that 
might halt the progression of the disease. 
As modest as the benefits of current 
treatments are, they nevertheless represent 
a major step in the pharmacotherapy of 
AD. Modest improvements mean more 
than symptomatic relief – they offer 
hope to AD patients, their physicians, 
and their caregivers. Therefore the latest 
draft guidelines issued by the UK National 
Institute for Clinical Excellence (NICE) 
recommending that AChEIs should be made 
available with restrictions to patients 
via NHS and that memantine should only 
be considered for clinical trials were 
met with strong resistance. Various AD 
organisations across Europe voiced their 
concerns about this approach, highlighting 
the need for NICE to assess its views 
and the implications that result if such 
guidelines are not revised. Even Alzheimer’s 
Europe, an umbrella organisation of 28 
national Alzheimer’s disease associations 
from 2 European countries, recently issued 
a press release that calls for NICE to revise 
its preliminary recommendations for the 
treatment of AD and allow patients at all 
stages of the illness to have access to the 
various drug treatments irrespective of the 
cost.
Indeed, there is strong evidence that 
these drugs enhance activities of daily 
living, reduce behavioural disturbances, 
stabilise cognitive impairment, decrease 
caregiver stress and may delay entry into 
nursing homes. Apart from reducing the 
symptoms of the disease, these drugs may 
offer neuroprotection, thus stabilising the 
degenerative process.
The future of pharmacotherapy in the 
treatment of AD looks very promising. 
Ongoing research has not only deepened 
our understanding of the disease but is also 
suggesting a number of different avenues that 
may be used to develop drugs to prevent and 
treat AD. These include agents that block the 
formation of plaques and tangles by inhibiting 
enzymes that help in their formation. Others 
include chemical compounds that dissolve 
amyloid and fibrils which are found in the 
brains of AD patients.16 Development of such 
drugs could also help in treating cognitive 
decline associated with normal ageing. 
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